STA
TXG icon

Summit Trail Advisors’s 10x Genomics TXG Stock Holding History

Summit Trail Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.73M Buy
269,768
+49,382
+22% +$987K 0.08% 141
2025
Q4 		$3.59M Sell
220,386
-4,259
-2% -$64.3K 0.06% 185
2025
Q3 		$2.63M Buy
224,645
+83,721
+59% +$1.09M 0.04% 310
2025
Q2 		$1.63M Buy
140,924
+104,885
+291% +$956K 0.03% 317
2025
Q1 		$315K Buy
36,039
+25,775
+251% +$325K 0.01% 320
2024
Q4 		$147K Buy
10,264
+178
+2% +$2.81K 0.01% 367
2024
Q3 		$228K Buy
+10,086
New +$209K 0.01% 639

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Trail Advisors's TXG Position: Q1 2026 in Review

Summit Trail Advisors increased its 10x Genomics (TXG) stake by 22% in Q1 2026, buying an estimated $987K and bringing the position to 269,768 shares worth $5.73M. The position accounts for 0.08% of the portfolio, ranked #141.

Summit Trail Advisors first reported a position in TXG in Q3 2024 and has held it in 7 quarters since. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Summit Trail Advisors held 269,768 shares of 10x Genomics worth $5.73M as of Q1 2026.
  • Summit Trail Advisors bought 49,382 10x Genomics shares in Q1 2026, an estimated $987K.
  • 10x Genomics made up 0.08% of Summit Trail Advisors's portfolio in Q1 2026, its #141 holding.
  • Summit Trail Advisors first reported a position in 10x Genomics in Q3 2024 and has held it in 7 quarters since.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.